Meeting of the Board of Scientific Counselors, Office of Readiness and Response, 29336-29337 [2024-08448]
Download as PDF
<![CDATA[
lotter on DSK11XQN23PROD with NOTICES1
29336
Federal Register / Vol. 89, No. 78 / Monday, April 22, 2024 / Notices
this time will not be considered for the
current membership cycle.
ADDRESSES: All nominations should be
emailed to nchhstppolicy@cdc.gov with
the subject line ‘‘CHAC 2025
Nomination.’’
FOR FURTHER INFORMATION CONTACT:
Marah Condit, M.S., Committee
Management Lead, Office of Policy,
Planning, and Partnerships, National
Center for HIV, Viral Hepatitis, STD,
and TB Prevention, Centers for Disease
Control and Prevention, 1600 Clifton
Road NE, Mailstop US8–6, Atlanta,
Georgia 30329–4027. Telephone: (404)
639–3423; Email: nchhstppolicy@
cdc.gov.
SUPPLEMENTARY INFORMATION: The
Secretary, Department of Health and
Human Services (HHS), and by
delegation, the Director, Centers for
Disease Control and Prevention (CDC),
and the Administrator, Health
Resources and Services Administration
(HRSA), are authorized by the Public
Health Service Act to: (1) conduct,
encourage, cooperate with, and assist
other appropriate public health
authorities, scientific institutions, and
scientists in the conduct of research,
investigations, experiments,
demonstrations, and studies relating to
the causes, diagnosis, treatment, control,
and prevention of physical and mental
diseases and other impairments; (2)
assist states and their political
subdivisions in preventing, suppressing,
and treating communicable diseases and
other preventable conditions and in
promoting health and well-being; (3)
assist public and non-profit private
entities in preventing, controlling and
treating sexually transmitted diseases
(STDs), including the human
immunodeficiency virus (HIV); (4)
improve health and achieve health
equity through access to quality services
and a skilled health workforce and
innovative programs; (5) support
healthcare services to persons with or
who experience risk for HIV, viral
hepatitis, and other STDs; (6) advance
the education of health professionals
and the public about HIV, viral
hepatitis, and other STDs; and (7)
improve adolescent and school health as
it pertains to HIV, viral hepatitis, and
STDs.
The CDC/HRSA Advisory Committee
on HIV, Viral Hepatitis and STD
Prevention and Treatment (CHAC)
meets at least two times each calendar
year, or at the discretion of the
Designated Federal Officers in
consultation with the CHAC co-chairs.
HHS policy stipulates that committee
membership be balanced in terms of
points of view represented and the
VerDate Sep<11>2014
06:41 Apr 20, 2024
Jkt 262001
committee’s function. Appointments
shall be made without discrimination
on the basis of age, race, ethnicity,
gender, sexual orientation, gender
identity, HIV status, disability, and
cultural, religious, or socioeconomic
status. Nominees must be U.S. citizens
and cannot be full-time employees of
the U.S. Government. Current
participation on Federal workgroups or
prior experience serving on a Federal
advisory committee does not disqualify
a candidate; however, HHS policy is to
avoid excessive individual service on
advisory committees and multiple
committee memberships. The CHAC
charter stipulates that the Committee
must include at least four members who
are persons with HIV. The Committee
may also include representation from
persons with lived experience, such as
those who have experienced viral
hepatitis, STDs, and drug use; state and
local health and education agencies;
HIV/viral hepatitis/STD communitybased organizations; and the ethics or
faith-based community.
Committee members are Special
Government Employees, requiring the
filing of financial disclosure reports at
the beginning of and annually during
their terms. Individuals who are
selected for appointment will be
required to provide detailed information
regarding their financial interests and,
for example, any work they do for the
federal government through research
grants or contracts. Disclosure of this
information is required in order for CDC
ethics officials to determine whether
there is a conflict between the SGE’s
public duties as a member of CHAC and
the SGE’s private interests, including an
appearance of a loss of impartiality as
defined by Federal laws and regulations,
and to identify any required remedial
action needed to address the potential
conflict.
CDC and HRSA review potential
candidates for CHAC membership when
a vacancy arises and provide a slate of
nominees for consideration to the
Secretary of HHS for final selection.
CDC and HRSA each publish a Federal
Register notice and will be using a joint
process to nominate nominees on a
rolling basis; thus, applications received
by CDC will be shared with HRSA for
consideration. Therefore, potential
candidates need only apply in response
to one of the Federal Register notices.
HHS notifies selected candidates of
their appointment near the start of the
term in December 2025, or as soon as
the HHS selection process is completed.
Note that the need for different expertise
varies from year to year and a candidate
who is not selected in one year may be
reconsidered in a subsequent year.
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
Candidates should submit the
following items:
D A letter of interest or personal
statement from the nominee stating how
the nominee’s expertise would inform
the work of CHAC
D A biographical sketch of the
nominee (500 words or fewer)
D Current curriculum vitae or resume,
including complete contact information
(telephone numbers, mailing address,
and email address)
D At least one letter of
recommendation from person(s) not
employed by HHS. Candidates may
submit letter(s) from current HHS
employees if they wish, but at least one
letter must be submitted by a person not
employed by an HHS agency (e.g., CDC,
National Institutes of Health, Food and
Drug Administration).
Nominations may be submitted by the
candidate or by the person/organization
recommending the candidate. CDC and
HRSA will collect and retain
nominations received for up to two
years to create a pool of potential CHAC
nominees. When a vacancy occurs, CDC
and HRSA will review nominations and
may contact nominees at that time.
The Director, Office of Strategic
Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2024–08447 Filed 4–19–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Meeting of the Board of Scientific
Counselors, Office of Readiness and
Response
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting.
AGENCY:
In accordance with the
Federal Advisory Committee Act, the
Centers for Disease Control and
Prevention (CDC) announces the
SUMMARY:
E:\FR\FM\22APN1.SGM
22APN1
lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 89, No. 78 / Monday, April 22, 2024 / Notices
following meeting for the Board of
Scientific Counselors, Office of
Readiness and Response, (BSC, ORR).
This virtual meeting is open to the
public. Time will be available for public
comment.
DATES: The meeting will be held on May
23, 2024, from 10 a.m. to 4:30 p.m.,
EDT.
ADDRESSES: Zoom virtual meeting. If
you wish to attend the meeting, please
register in advance by accessing the link
at https://cdc.zoomgov.com/webinar/
register/WN_kNZWpr8KRVGTGN0ERE_
1Cg#/registration. Instructions to access
the meeting will be provided following
registration.
FOR FURTHER INFORMATION CONTACT:
Dometa Ouisley, Public Health Analyst,
Office of Science and Laboratory
Readiness, Office of Readiness and
Response, Centers for Disease Control
and Prevention, 1600 Clifton Road NE,
Mailstop H21–6, Atlanta, Georgia
30329–4027. Telephone: (404) 639–
7450; Email: DOuisley@cdc.gov.
SUPPLEMENTARY INFORMATION:
Purpose: The Board of Scientific
Counselors, Office of Readiness and
Response provides advice and guidance
to the Secretary, Department of Health
and Human Services (HHS); the
Assistant Secretary for Health, HHS; the
Director, Centers for Disease Control
and Prevention (CDC); and the Director,
Office of Readiness and Response
(ORR), CDC. The Board recommends
strategies and goals for readiness and
response activities pertaining to
programs and research within the
agency and the ORR divisions and
monitors the overall strategic direction
and focus of the ORR divisions and
offices. The Board may also perform
second-level peer review of applications
for grants-in-aid for research and
research training activities, cooperative
agreements, and research contract
proposals relating to the broad areas
within the center. For additional
information about the Board, please
visit https://www.cdc.gov/orr/bsc/
index.htm.
Matters to be Considered: Agenda
topics for the meeting include: (1) ORR
Updates, (2) ORR Division Directors
Follow-up Discussion, (3) Polio
Containment Working Group Updates,
(4) Health Equity Working Group
Updates, and (5) ORR Science Agenda
Presentation and Discussion. Agenda
items are subject to change as priorities
dictate.
The Director, Office of Strategic
Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
VerDate Sep<11>2014
06:41 Apr 20, 2024
Jkt 262001
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2024–08448 Filed 4–19–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[CMS–1821–N]
Medicare Program Public Meeting for
New Revisions to the Healthcare
Common Procedure Coding System
(HCPCS) Coding—May 28–30, 2024
Centers for Medicare &
Medicaid Services (CMS), Department
of Health and Human Services (HHS).
ACTION: Notice.
AGENCY:
This notice announces the
dates and times of the virtual Healthcare
Common Procedure Coding System
(HCPCS) public meeting to be held from
May 28, 2024, through May 30, 2024, to
discuss CMS’ preliminary coding,
Medicare benefit category, and payment
determinations, if applicable, for new
revisions to the HCPCS Level II code set
for non-drug and non-biological items
and services, as well as how to register
for those meetings.
DATES: Virtual Meeting Dates: Tuesday,
May 28, 2024, 9 a.m. to 5 p.m. Eastern
Time (ET); Wednesday, May 29, 2024, 9
a.m. to 5 p.m. ET; and Thursday, May
30, 2024, 9 a.m. to 5 p.m. ET.
ADDRESSES: Virtual Meeting Location:
The HCPCS public meetings will be
held virtually via Zoom only.
FOR FURTHER INFORMATION CONTACT:
Sundus Ashar, (410) 786–0750,
Sundus.ashar1@cms.hhs.gov, or
HCPCS@cms.hhs.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
I. Background
On December 21, 2000, Congress
enacted the Medicare, Medicaid, and
the Children’s Health Insurance
Program (CHIP) Benefits Improvement
and Protection Act of 2000 (BIPA) (Pub.
L. 106–554). Section 531(b) of BIPA
mandated that the Secretary establish
procedures that permit public
consultation for coding and payment
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
29337
determinations for new durable medical
equipment (DME) under Medicare Part
B of title XVIII of the Social Security Act
(the Act). In the November 23, 2001,
Federal Register (66 FR 58743), we
published a notice providing
information regarding the establishment
of the annual public meeting process for
DME.
In 2020, we implemented changes to
our HCPCS Level II coding procedures,
including the establishment of quarterly
coding cycles for drugs and biological
products and biannual coding cycles for
non-drug and non-biological items and
services.
In the December 28, 2021, Federal
Register (86 FR 73860), we published a
final rule that established procedures for
making Medicare benefit category and
payment determinations for new items
and services that are DME, prosthetic
devices, orthotics and prosthetics,
therapeutic shoes and inserts, surgical
dressings, or splints, casts, and other
devices used for reductions of fractures
and dislocations under Medicare Part B.
II. Public Meeting Agendas
Prior to registering to attend a virtual
public meeting, all potential
participants and other attendees are
advised to review the public meeting
agendas at https://www.cms.gov/
Medicare/Coding/MedHCPCSGenInfo/
HCPCSPublicMeetings, which identify
CMS’ preliminary coding, Medicare
benefit category, and payment
determinations, if applicable, and the
date each item will be discussed. In
establishing the public meeting agendas,
CMS may group multiple, related code
applications under the same agenda
item.
III. Virtual Meeting Registration
The May 28, 2024, through May 30,
2024, HCPCS public meetings will be
virtual and available for remote audio
attendance and participation only via
Zoom. The Zoom link and registration
instructions will be posted in the
Guidelines for Participation in HCPCS
Public Meetings document on the CMS
website at https://www.cms.gov/
Medicare/Coding/MedHCPCSGenInfo/
HCPCSPublicMeetings and in an
announcement on the HCPCS General
Information page at https://
www.cms.gov/medicare/coding-billing/
healthcare-common-procedure-system.
The same website also contains detailed
information on how attendees can join
the virtual public meetings using Zoom,
including dial-in information. All
individuals who plan to speak (15 or 5
minutes) at the virtual public meetings
must register by 5 p.m. ET on Friday,
May 17, 2024. All participants and other
E:\FR\FM\22APN1.SGM
22APN1
]]>Agencies
[Federal Register Volume 89, Number 78 (Monday, April 22, 2024)]
[Notices]
[Pages 29336-29337]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-08448]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Meeting of the Board of Scientific Counselors, Office of
Readiness and Response
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, the
Centers for Disease Control and Prevention (CDC) announces the
[[Page 29337]]
following meeting for the Board of Scientific Counselors, Office of
Readiness and Response, (BSC, ORR). This virtual meeting is open to the
public. Time will be available for public comment.
DATES: The meeting will be held on May 23, 2024, from 10 a.m. to 4:30
p.m., EDT.
ADDRESSES: Zoom virtual meeting. If you wish to attend the meeting,
please register in advance by accessing the link at https://cdc.zoomgov.com/webinar/register/WN_kNZWpr8KRVGTGN0ERE_1Cg#/registration. Instructions to access the meeting will be provided
following registration.
FOR FURTHER INFORMATION CONTACT: Dometa Ouisley, Public Health Analyst,
Office of Science and Laboratory Readiness, Office of Readiness and
Response, Centers for Disease Control and Prevention, 1600 Clifton Road
NE, Mailstop H21-6, Atlanta, Georgia 30329-4027. Telephone: (404) 639-
7450; Email: [email protected].
SUPPLEMENTARY INFORMATION:
Purpose: The Board of Scientific Counselors, Office of Readiness
and Response provides advice and guidance to the Secretary, Department
of Health and Human Services (HHS); the Assistant Secretary for Health,
HHS; the Director, Centers for Disease Control and Prevention (CDC);
and the Director, Office of Readiness and Response (ORR), CDC. The
Board recommends strategies and goals for readiness and response
activities pertaining to programs and research within the agency and
the ORR divisions and monitors the overall strategic direction and
focus of the ORR divisions and offices. The Board may also perform
second-level peer review of applications for grants-in-aid for research
and research training activities, cooperative agreements, and research
contract proposals relating to the broad areas within the center. For
additional information about the Board, please visit https://www.cdc.gov/orr/bsc/index.htm.
Matters to be Considered: Agenda topics for the meeting include:
(1) ORR Updates, (2) ORR Division Directors Follow-up Discussion, (3)
Polio Containment Working Group Updates, (4) Health Equity Working
Group Updates, and (5) ORR Science Agenda Presentation and Discussion.
Agenda items are subject to change as priorities dictate.
The Director, Office of Strategic Business Initiatives, Office of
the Chief Operating Officer, Centers for Disease Control and
Prevention, has been delegated the authority to sign Federal Register
notices pertaining to announcements of meetings and other committee
management activities, for both the Centers for Disease Control and
Prevention and the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2024-08448 Filed 4-19-24; 8:45 am]
BILLING CODE 4163-18-P
